Bristol Myers Squibb (BMY) Change in Account Payables (2009 - 2026)

Bristol Myers Squibb has disclosed Change in Account Payables across 18 years of filings, most recently posting $409.0 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 581.18% year-over-year to $409.0 million; the TTM figure through Mar 2026 stood at $492.0 million (up 344.78% YoY), while the FY2025 annual figure was -$2.0 million, down 101.09% from the prior year.
• Change in Account Payables rose to $409.0 million in Q1 2026, from -$90.0 million in the prior quarter.
• Over the last five years, Change in Account Payables for BMY reached as high as $517.0 million in Q4 2024 and fell as low as -$374.0 million in Q3 2024.
• The 5-year median for Change in Account Payables is $13.0 million (2025), against an average of $52.8 million.
• The widest YoY moves for Change in Account Payables: up 713.04% in 2023, down 768.42% in 2023.
• A 5-year view of Change in Account Payables shows it stood at $405.0 million in 2022, then increased by 9.63% to $444.0 million in 2023, then rose by 16.44% to $517.0 million in 2024, then sank by 117.41% to -$90.0 million in 2025, then soared by 554.44% to $409.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $409.0 million, -$90.0 million, and $160.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.